BRISTOL-MYERS SQUIBB COMPANY Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 56,28 USD | -0,65% |
|
-4,35% | +9,69% |
| 10/12 | Agilent Cancer Diagnostic Assay ontvangt certificering om te voldoen aan nieuwe EU-regelgeving | MT |
| 10/12 | BRISTOL-MYERS SQUIBB COMPANY : Berenberg Bank handhaaft het Neutraal advies | ZM |
Voorlopige winst- en verliesrekening: Bristol-Myers Squibb Company
| Fiscaal tijdperk: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 26.145 | 42.518 | 46.385 | 46.159 | 45.006 | 47.468 | 46.889 | 44.212 |
| Variatie | - | 62,62% | 9,09% | -0,49% | -2,5% | 5,47% | -1,22% | -5,71% |
| EBITDA 1 | 9.945 | 18.118 | 20.493 | 20.123 | 17.498 | 5.460 | 18.212 | 15.881 |
| Variatie | - | 82,18% | 13,11% | -1,81% | -13,04% | -68,79% | 233,53% | -12,8% |
| Bedrijfsresultaat (EBIT) 1 | 8.199 | 17.426 | 19.830 | 19.442 | 16.785 | 4.707 | 17.162 | 15.566 |
| Variatie | - | 112,54% | 13,8% | -1,96% | -13,67% | -71,96% | 264,61% | -9,3% |
| Betaalde rente 1 | -192 | -1.299 | -1.295 | -1.232 | -1.166 | -1.967 | -1.714 | -1.485 |
| Resultaat voor belastingen (EBT) 1 | 4.975 | -6.871 | 8.098 | 7.713 | 8.440 | -6.919 | 8.205 | 7.170 |
| Variatie | - | - | - | -4,75% | 9,43% | - | - | -12,61% |
| Nettowinst (verlies) 1 | 3.439 | -9.015 | 6.994 | 6.327 | 8.025 | -6.600 | 9.688 | 9.913 |
| Variatie | - | - | - | -9,54% | 26,84% | - | - | 2,32% |
| Datum van publicatie | 06-02-20 | 04-02-21 | 04-02-22 | 02-02-23 | 02-02-24 | - | - | - |
1USD in Miljoen
Geschatte gegevens
Balansprognose: Bristol-Myers Squibb Company
| Fiscaal tijdperk: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuld 1 | 31.340 | 34.412 | 27.587 | 30.067 | 27.128 | 38.374 | 30.869 | 24.442 |
| Variatie | - | 9,8% | -19,83% | 8,99% | -9,77% | 41,46% | -19,56% | -20,82% |
| Datum van publicatie | 06-02-20 | 04-02-21 | 04-02-22 | 02-02-23 | 02-02-24 | - | - | - |
1USD in Miljoen
Geschatte gegevens
Verwachte kasstroom: Bristol-Myers Squibb Company
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 836 | 753 | 973 | 1.118 | 1.209 | 1.194 | 1.085 | 1.051 |
| Variatie | - | -9,93% | 29,22% | 14,9% | 8,14% | -1,27% | -9,12% | -3,1% |
| Vrije kasstroom (FCF) 1 | 7.231 | 13.299 | 15.234 | 11.948 | 12.651 | 16.029 | 15.950 | 14.353 |
| Variatie | - | 83,92% | 14,55% | -21,57% | 5,88% | 26,7% | -0,49% | -10,01% |
| Datum van publicatie | 06-02-20 | 04-02-21 | 04-02-22 | 02-02-23 | 02-02-24 | - | - | - |
1USD in Miljoen
Geschatte gegevens
Verwachte financiële ratio's: Bristol-Myers Squibb Company
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
Winstgevendheid | ||||||||
| EBITDA-marge (%) | 38,04% | 42,61% | 44,18% | 43,59% | 38,88% | 11,5% | 38,84% | 35,92% |
| EBIT-marge (%) | 31,36% | 40,98% | 42,75% | 42,12% | 37,3% | 9,92% | 36,6% | 35,21% |
| EBT-marge (%) | 19,03% | -16,16% | 17,46% | 16,71% | 18,75% | -14,58% | 17,5% | 16,22% |
| Nettomarge (%) | 13,15% | -21,2% | 15,08% | 13,71% | 17,83% | -13,9% | 20,66% | 22,42% |
| FCF-marge (%) | 27,66% | 31,28% | 32,84% | 25,88% | 28,11% | 33,77% | 34,02% | 32,46% |
| Vrije kasstroom/nettoresultaat (%) | 210,26% | -147,52% | 217,82% | 188,84% | 157,64% | -242,87% | 164,64% | 144,8% |
Winstgevendheid | ||||||||
| ROA | - | 11,89% | 14,8% | 16,04% | 8,36% | -5,2% | 13,21% | 12,23% |
| ROE | 24,49% | 33,04% | 45,69% | 49,35% | 51,57% | 8,13% | 77,48% | 62,52% |
Financiële gezondheid | ||||||||
| Hefboom (schuld/ebitda) | 3,15x | 1,9x | 1,35x | 1,49x | 1,55x | 7,03x | 1,69x | 1,54x |
| Schuld/vrije kasstroom | 4,33x | 2,59x | 1,81x | 2,52x | 2,14x | 2,39x | 1,94x | 1,7x |
Kapitaalintensiteit | ||||||||
| Kapitaaluitgaven/omzet (%) | 3,2% | 1,77% | 2,1% | 2,42% | 2,69% | 2,51% | 2,31% | 2,38% |
| CAPEX / EBITDA (%) | 8,41% | 4,16% | 4,75% | 5,56% | 6,91% | 21,86% | 5,96% | 6,62% |
| CAPEX / FCF (%) | 11,56% | 5,66% | 6,39% | 9,36% | 9,56% | 7,45% | 6,8% | 7,32% |
Bestanddelen per aandeel | ||||||||
| Kasstroom per aandeel 1 | 4,712 | 6,223 | 7,297 | 6,089 | 6,67 | 8,37 | 6,941 | 7,632 |
| Variatie | - | 32,07% | 17,26% | -16,56% | 9,54% | 25,48% | -17,07% | 9,96% |
| Dividend per aandeel 1 | 1,68 | 1,84 | 2,01 | 2,19 | 2,31 | 2,388 | 2,475 | 2,536 |
| Variatie | - | 9,52% | 9,24% | 8,96% | 5,48% | 3,39% | 3,64% | 2,46% |
| Nettoactief per aandeel 1 | 30,26 | 16,75 | 16,7 | 14,34 | 14,73 | 9,098 | 10,77 | 11,89 |
| Variatie | - | -44,65% | -0,33% | -14,11% | 2,72% | -38,24% | 18,35% | 10,38% |
| WPA 1 | - | -3,99 | 3,12 | 2,95 | 3,86 | -3,186 | 5,166 | 5,177 |
| Variatie | - | - | -178,2% | -5,45% | 30,85% | -182,55% | -262,14% | 0,2% |
| Aantal aandelen (in duizend) | 2.344.185 | 2.259.752 | 2.219.645 | 2.219.645 | 2.034.758 | 2.028.177 | 2.028.177 | 2.028.177 |
| Datum van publicatie | 06-02-20 | 04-02-21 | 04-02-22 | 02-02-23 | 02-02-24 | - | - | - |
1USD
Geschatte gegevens
| 2024 * | 2025 * | |
|---|---|---|
| K/w-verhouding | -17,7x | 10,9x |
| PBR-ratio | 6,19x | 5,23x |
| EV/omzet | 3,21x | 3,09x |
| Dividendrendement | 4,24% | 4,4% |
Meer waarderingsratio's
* Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Verkoop
Koop
Gemiddeld advies
Houden
Aantal analisten
26
Laatste slotkoers
56,28USD
Gemiddelde koersdoel
60,58USD
Spread / Gemiddelde doel
+7,64%
